# EDGAR Filing Document

**Accession Number:** 0001095981
**File Stem:** 0001193125-26-227059
**Filing Date:** 2026-5
**Character Count:** 7475
**Document Hash:** a1f167f574740e4ed495c4934010a789
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-227059.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001193125-26-227059

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260514

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLUS THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001095981
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 330827593
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34375
- **FILM NUMBER:** 26989123

**BUSINESS ADDRESS:**
- **STREET 1:** 4200 MARATHON BLVD.
- **STREET 2:** SUITE 200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78756
- **BUSINESS PHONE:** 737.255.7194

**MAIL ADDRESS:**
- **STREET 1:** 4200 MARATHON BLVD.
- **STREET 2:** SUITE 200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78756

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTORI THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20050712

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MACROPORE INC
- **DATE OF NAME CHANGE:** 20010320

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 14, 2026<br>

------

PLUS THERAPEUTICS, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-34375 | 33-0827593 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 6420 LEVIT GREEN BOULEVARD<br>Suite 310 |  |  |
| Houston**,** Texas |  | 77021 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (737) 255-7194<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | PSTV | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2026 Annual Meeting of Stockholders of Plus Therapeutics, Inc. (the "Company") was held on May 14, 2026 (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on four proposals, as described in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 31, 2026 (the "Proxy Statement"). All share amounts disclosed herein are presented before giving effect to the Company's 1-for-25 reverse stock split effective on April 2, 2026.

The Company had 171,550,698 shares of common stock issued and outstanding at the close of business on March 18, 2026, the record date for eligibility to vote at the Annual Meeting. The holders of 64,857,321 shares of the Company's issued and outstanding common stock were represented in person virtually or represented by valid proxy at the Annual Meeting, constituting a quorum.

The vote results detailed below represent final results as certified by the inspector of elections.

*Proposal No. 1 - Election of Directors.* 

The Company's stockholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the "Board") to hold office for a term expiring at the Company's Annual Meeting of Stockholders in 2027 and until each such person's successors is duly elected and qualified, or until his or her earlier death, resignation or removal:

---

| | | | |
|:---|:---|:---|:---|
|  | Votes For | Votes Withheld | Broker Non-Votes |
| &nbsp;&nbsp;&nbsp;Howard Clowes | 11863579 | 2186724 | 50807018 |
| &nbsp;&nbsp;&nbsp;An van Es-Johansson, M.D. | 12384866 | 1665437 | 50807018 |
| &nbsp;&nbsp;&nbsp;Richard J. Hawkins | 12344152 | 1706151 | 50807018 |
| &nbsp;&nbsp;&nbsp;Marc H. Hedrick, M.D. | 12350511 | 1699792 | 50807018 |
| &nbsp;&nbsp;&nbsp;Ronald A. Andrews | 12417138 | 1633165 | 50807018 |
| &nbsp;&nbsp;&nbsp;Kyle Guse, Esq., MBA, CPA | 12384591 | 1665712 | 50807018 |

---

*Proposal No. 2 - Ratification of Appointment of Independent Registered Public Accounting Firm.* 

The Company's stockholders ratified the appointment of CBIZ CPAs, P.C. as the Company's independent registered public accounting firm for the 2026 fiscal year. The votes regarding this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 60,860,051 | 2,292,062 | 1,705,208 | 0 |

---

*Proposal No. 3 - Advisory Vote on the Compensation of Named Executive Officers.* 

The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers. The votes regarding this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 10,389,498 | 3,364,694 | 296,111 | 50,807,018 |

---

*Proposal No. 4 – Sixth Amendment and Restatement of the Company's 2020 Stock Incentive Plan.* 

The Company's stockholders approved the sixth amendment and restatement of the Company's 2020 Stock Incentive Plan. The votes regarding this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 7,976,002 | 5,648,887 | 425,414 | 50,807,018 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **PLUS THERAPEUTICS, INC.**  |
| Date: | May 15, 2026 | By:  | /s/ Marc H. Hedrick, M.D.  |
|  |  |  | Marc H. Hedrick, M.D.<br>President and Chief Executive Officer  |

---

------